|
Most recent content
(20 Jun 2008):
|
- Phase I and Clinical Pharmacology
Phase I and Pharmacokinetic Study of Lapatinib and Docetaxel in Patients With Advanced Cancer
- Patricia M. LoRusso, Suzanne F. Jones, Kevin M. Koch, Nikita Arya, Ronald A. Fleming, Jill Loftiss, Lini Pandite, Shirish Gadgeel, Barbara L. Weber, and Howard A. Burris, III
J. Clin. Oncol. 2008; 26: 3051-3056.
[Abstract]
[Full text]
[PDF]
|
Past content
(since Jan 2005):
|
- Articles
Phase I Dose Escalation and Pharmacokinetic Study of Lapatinib in Combination With Trastuzumab in Patients With Advanced ErbB2-Positive Breast Cancer
- Anna Maria Storniolo, Mark D. Pegram, Beth Overmoyer, Paula Silverman, Nancy W. Peacock, Suzanne F. Jones, Jill Loftiss, Nikita Arya, Kevin M. Koch, Elaine Paul, Lini Pandite, Ronald A. Fleming, Peter F. Lebowitz, Peter T.C. Ho, and Howard A. Burris, III
J. Clin. Oncol. 10.1200/JCO.2007.13.5202.
[Abstract]
[PDF]
- Articles
Efficacy and Safety of Lapatinib As First-Line Therapy for ErbB2-Amplified Locally Advanced or Metastatic Breast Cancer
- Henry L. Gomez, Dinesh C. Doval, Miguel A. Chavez, Peter C.-S. Ang, Zeba Aziz, Shona Nag, Christina Ng, Sandra X. Franco, Louis W.C. Chow, Michael C. Arbushites, Michelle A. Casey, Mark S. Berger, Steven H. Stein, and George W. Sledge
J. Clin. Oncol. 10.1200/JCO.2007.14.0590.
[Abstract]
[PDF]
- Articles
Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral, Small-Molecule Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor AZD6244 (ARRY-142886) in Patients With Advanced Cancers
- Alex A. Adjei, Roger B. Cohen, Wilbur Franklin, Clive Morris, David Wilson, Julian R. Molina, Lorelei J. Hanson, Lia Gore, Laura Chow, Stephen Leong, Lara Maloney, Gilad Gordon, Heidi Simmons, Allison Marlow, Kevin Litwiler, Suzy Brown, Gregory Poch, Katie Kane, Jerry Haney, and S. Gail Eckhardt
J. Clin. Oncol. 10.1200/JCO.2007.14.4956.
[Abstract]
[PDF]
- Phase I and Clinical Pharmacology
Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With Advanced Solid Tumors
- Anne O'Donnell, Sandrine Faivre, Howard A. Burris, III, Daniel Rea, Vassiliki Papadimitrakopoulou, Nicholas Shand, Heidi A. Lane, Katharine Hazell, Ulrike Zoellner, John M. Kovarik, Cathryn Brock, Suzanne Jones, Eric Raymond, and Ian Judson
J. Clin. Oncol. 2008; 26: 1588-1595.
[Abstract]
[Full text]
[PDF]
- Phase I and Clinical Pharmacology
Identifying Optimal Biologic Doses of Everolimus (RAD001) in Patients With Cancer Based on the Modeling of Preclinical and Clinical Pharmacokinetic and Pharmacodynamic Data
- Chiaki Tanaka, Terence O’Reilly, John M. Kovarik, Nicholas Shand, Katharine Hazell, Ian Judson, Eric Raymond, Sabine Zumstein-Mecker, Christine Stephan, Anne Boulay, Marc Hattenberger, George Thomas, and Heidi A. Lane
J. Clin. Oncol. 2008; 26: 1596-1602.
[Abstract]
[Full text]
[PDF]
- Phase I and Clinical Pharmacology
Dose- and Schedule-Dependent Inhibition of the Mammalian Target of Rapamycin Pathway With Everolimus: A Phase I Tumor Pharmacodynamic Study in Patients With Advanced Solid Tumors
- Josep Tabernero, Federico Rojo, Emiliano Calvo, Howard Burris, Ian Judson, Katharine Hazell, Erika Martinelli, Santiago Ramon y Cajal, Suzanne Jones, Laura Vidal, Nicholas Shand, Teresa Macarulla, Francisco Javier Ramos, Sasa Dimitrijevic, Ulrike Zoellner, Pui Tang, Michael Stumm, Heidi A. Lane, David Lebwohl, and José Baselga
J. Clin. Oncol. 2008; 26: 1603-1610.
[Abstract]
[Full text]
[PDF]
- Articles
Phase I Trial of the Prostate-Specific Membrane Antigen–Directed Immunoconjugate MLN2704 in Patients With Progressive Metastatic Castration-Resistant Prostate Cancer
- Matthew D. Galsky, Mario Eisenberger, Sandra Moore-Cooper, W. Kevin Kelly, Susan F. Slovin, Anthony DeLaCruz, Yih Lee, Iain J. Webb, and Howard I. Scher
J. Clin. Oncol. 10.1200/JCO.2007.15.0532.
[Abstract]
[PDF]
- Articles
Dose Selection in Phase I Studies: Why We Should Always Go for the Top
- Stefan Sleijfer and Erik Wiemer
J. Clin. Oncol. 10.1200/JCO.2007.15.5192.
[Abstract]
[PDF]
- Phase I and Clinical Pharmacology
Pharmacogenomic and Pharmacokinetic Determinants of Erlotinib Toxicity
- Charles M. Rudin, Wanqing Liu, Apurva Desai, Theodore Karrison, Xuemin Jiang, Linda Janisch, Soma Das, Jacqueline Ramirez, Balasubramanian Poonkuzhali, Erin Schuetz, Donna Lee Fackenthal, Peixian Chen, Deborah K. Armstrong, Julie R. Brahmer, Gini F. Fleming, Everett E. Vokes, Michael A. Carducci, and Mark J. Ratain
J. Clin. Oncol. 2008; 26: 1119-1127.
[Abstract]
[Full text]
[PDF]
|
